Author Interviews, Disability Research, Johns Hopkins, Pain Research, Rheumatology / 27.03.2014
MedicalResearch.com Interview with:
Tim Bongartz, M.D.
Associate Professor of Medicine
Department of Rheumatology
Mayo Clinic, Minnesota
MedicalResearch.com: What are the main study findings?
Dr. Bongartz: Dual-energy computed tomography (DECT) is an imaging methods that has been in use for many years to classify the material of renal stones. Our study demonstrates that this technology can be useful in identifying monosodium urate deposits in and around joint, allowing to diagnose patients with gout with overall high sensitivity and specificity. Importantly, a stratified analysis of patient subgroups revealed that DECT is less accurate in diagnosing patients with a first flare of gout, emphasizing the importance of careful patient selection when using this new technology. In a "diagnostic-yield" substudy, we explored the question how much DECT could contribute to correctly diagnose patients where clinicians did have a high level of suspicion for gout, but synovial fluid aspiration results came back negative. In about a third of these patients with negative routine testing, we could confirm a diagnosis of gout through use of DECT.
MedicalResearch.com Interview with:
Mary-Ann Fitzcharles, MB, ChB, MRCP(UK), FRCP(C)
McGill University Health Centre
Division of Rheumatology and Alan Edwards Pain Management Unit
MedicalResearch.com: What are the highlights of your review?
Dr. Fitzcharles: Thank you for your interest in the review article which will shortly be published in Arthritis Care & Research. This was not a research study but rather a review focused towards the use of herbal cannabis for patients with rheumatic diseases.
The essence of our message after a thorough review of the literature is that there is not a single study published regarding efficacy or side effects of herbal cannabis in the rheumatic diseases. It is notable that almost 2 thirds of persons using herbal cannabis for therapeutic reasons report use for musculoskeletal complaints. In the 21st century, we cannot rely upon heresay or anecdote to justify use of a treatment intervention. It is unacceptable to recommend use of a substance without knowledge of concentration of molecules in the product, any knowledge of blood concentrations that might have a positive or negative effect, and formal study in defined patient populations with acceptable endpoint criteria and evidence for short and long term risks.
MedicalResearch.com Interview:
Dr. John McBeth
Arthritis Research UK Primary Care Centre
Keele University in Staffordshire
MedicalResearch.com: What are the main findings of the study?
Dr. McBeth: In this study, reporting musculoskeletal pain was common with just under half of participants reporting some pain and one quarter reporting widespread pain. Of those who were free of WP at baseline, 19% reported new onset widespread pain at three year follow up.
In addition to osteoarthritis, sleep, cognitive impairment, anxiety and physical health independently predicted the onset of widespread pain and are important treatment targets. In this study non-restorative sleep was the strongest predictor of new onset widespread pain. Sleep is a modifiable target that could improve outcome in this patient group.
MedicalResearch.com Interview with:
Gabriela Schmajuk M.D. M.S.
Department of Medicine (Rheumatology)
University of California, San Francisco
San Francisco VA Medical Center
San Francisco, CA 94121
MedicalResearch.com: What are the main findings of the study?
Dr. Schmajuk: Our main findings were that moderate LFT abnormalities were uncommon
in the first 7 months of methotrexate use among new users, and more
likely to occur in patients with obesity, untreated high cholesterol,
pre-methotrexate LFT elevations, biologic agent use, and lack of folic
acid supplementation.
MedicalResearch.com Interview with:
Dr. Laura Coates
Division of Rheumatic and Musculoskeletal Disease
Chapel Allerton Hospital Chapeltown Road Leeds
NIHR Clinical Lecturer at the University of Leeds
MedicalResearch.com: What are the main findings of the study?
Answer: The TICOPA study showed that treating patients with early psoriatic
arthritis to an objective target with regular review improved
patient's clinical outcome both in terms of arthritis and skin
psoriasis. There was an increase in adverse events in the tight
control arm but only 4 serious infections seen in the tight control
arm that were thought to be related to treatment (2 cases of
cellulitis, 2 cases of chest infection).
MedicalResearch.com Interview with:
Eric Matteson, M.D.
Rheumatology Chair
Mayo Clinic in Rochester, Minn.
MedicalResearch.com: What are the main findings of the studies?
Dr. Matteson: “The main finding is that patients with severe rheumatoid arthritis have a higher risk of heart disease. Further, women who experience early menopause also have a higher risk of heart disease.”
MedicalResearch.com Interview with:
Dr. Janet E Pope
Division of Rheumatology, Department of Medicine
The University of Western Ontario, St Joseph's Health Centre
268 Grosvenor Street, London, ON, Canada N6A 4V2
MedicalResearch.com: What are the main findings of the study?
Dr. Pope: We performed a RCT of patients who were stable for 6 months of etanercept added to methotrexate (inadequate responders to Mtx) who were randomized to stopping Mtx or continuing Mtx to determine if in the next 6 months (and later as the trial continues) the response rate would be the same if Mtx was discontinued. Overall, Mtx + etanercept was not statistically equivalent to etanercept alone (ie non-inferiority did not occur); implying 6 months after stopping Mtx, the etanercept patients on monotherapy performed slightly less well than those on combination therapy.
Hemodialysis.com Interview with: Dr. David W. Powell PhD Associate Director of Clinical Proteomics Assistant Professor of Medicine Assistant Professor of Biochemistry and Molecular...
MedicalResearch.com Interview with:
Marloes Heijstek MD
University Medical Center, Wilhelmina Children's Hospital
Department of Pediatric Immunology and Rheumatology
Room number KC 03.063.0
P.O. Box 85090 Lundlaan 6
3508 AB Utrecht
MedicalResearch.com: What are the main findings of the study?
Dr. Heijstek: The main findings of our study are that MMR booster vaccination does not affect JIA disease, does not cause flares of arthritis and induces high rates of protective immunity.
This site complies with the HONcode standard for trustworthy health information:
verify here.